[04]
Investigation Desk
SWITCH AUDIT DESK

Discrepancies & Conflict Adjudication

HUMAN-IN-THE-LOOP SWITCH REASONING • CROSS-EXAMINATION OF CONTRADICTIONS

1 CRITICAL3 OPEN
ACTIVE CASE LOG (3)SELECT TO ADJUDICATE
CASE-BIO-01critical
open

FDA Form 1572 Principal Investigator Sign-Off Mismatch

FDA Form 1572 designates Dr. Eleanor Vance as primary sponsor representative, whereas Vendor MSA Amendment 3 names Dr. Marcus Thorne. Discrepancy triggers an automatic clinical trial hold on Phase II Oncology protocols.

TYPE: CONTRADICTIONRegulatory-Audit-Q3-2024.pdf
CASE-BIO-02high
open

$140,000 Spectrometry Lab Contract Auto-Renewal

Apex BioAnalytical master agreement auto-renews for 12 months ($140,000 commitment) on November 15 unless written opt-out is received 30 days prior (October 15). The transition charter lacks a designated signatory.

TYPE: OUTDATED_DEADLINEVendor-Master-Agreement-2023.docx
CASE-BIO-03high
open

Compound C-409 Patent Co-Inventor Assignment Gap

Exhibit C (Co-inventor assignment declaration) referenced in the patent memo is absent from the legal archive binder. Threatens priority rights for European patent counterpart filing due December 15.

TYPE: OWNERSHIP_GAPPatent-Filing-Memo-RevB.pdf
// CONTRADICTIONSEVERITY: CRITICAL
STATUS: OPEN

FDA Form 1572 Principal Investigator Sign-Off Mismatch

RISK VECTOR & OPERATIONAL IMPACT

FDA Form 1572 designates Dr. Eleanor Vance as primary sponsor representative, whereas Vendor MSA Amendment 3 names Dr. Marcus Thorne. Discrepancy triggers an automatic clinical trial hold on Phase II Oncology protocols.

VERBATIM EVIDENCE CROSS-EXAMINATION
RECORD AConflicting Evidence
“Box 1: Sponsor Representative designated as Dr. Eleanor Vance. Box 6: Clinical protocol trial execution managed by Dr. Marcus Thorne.”
SOURCE: Regulatory-Audit-Q3-2024.pdf
RECORD BMissing Record
“Execution Sponsor is hereby reassigned exclusively to Dr. Marcus Thorne effective October 1, 2024.”
SOURCE: Counterpart Archival Instrument
HUMAN RESOLUTION SIGN-OFF